LAL method endotoxin analysis for pharmaceutical, injectable, and medical device applications. USP <85>-compliant results with ISO 17025-accredited certification.
Endotoxin testing detects bacterial lipopolysaccharide (LPS) — a pyrogen that can trigger fever, septic shock, or death when introduced intravenously. Any pharmaceutical product, biologic, or medical device that contacts blood, cerebrospinal fluid, or parenteral tissue must be tested for endotoxins before release.
Prodigy Labs performs endotoxin testing using the kinetic turbidimetric LAL (Limulus Amebocyte Lysate) method, standardized under USP <85>. LAL reagent — derived from the blood cells of the Atlantic horseshoe crab (Limulus polyphemus) — contains a clotting cascade that reacts specifically and sensitively to bacterial endotoxin.
The kinetic turbidimetric technique measures the rate of optical absorbance change as the clot forms, producing a reaction time that is inversely proportional to endotoxin concentration. This allows precise quantification in Endotoxin Units (EU/mL or EU/mg) across a validated standard curve, typically spanning 0.005–50 EU/mL.
Results are reported against pharmacopoeial reference standard endotoxin (RSE) and include spike recovery and inhibition/enhancement controls as required by USP <85>.
Regulatory agencies require endotoxin testing for products that have direct contact with blood or sterile tissue:
Sample is diluted in LAL-grade water to the maximum valid dilution (MVD). Inhibition/enhancement testing confirms matrix compatibility. Depyrogenated glassware and LAL reagent water (LRW) are used throughout.
Reconstituted LAL reagent is added to sample, standard, and control wells in a microplate. The plate incubates at 37°C while a spectrophotometer continuously measures turbidity at 405 nm.
Reaction onset time (T) is plotted against the log-linear standard curve. Endotoxin concentration is back-calculated in EU/mL (or EU/mg, EU/device). Results are compared to the product endotoxin limit and reported on an ISO 17025 COA.
Sensitivity: Kinetic turbidimetric LAL routinely achieves a lower limit of detection of 0.005 EU/mL, making it suitable for high-potency injectables with strict endotoxin limits.
If your product contacts blood, sterile tissue, or parenteral fluid pathways, endotoxin testing is not optional — it is a regulatory prerequisite for release.
Injectable drug products — small molecules, biologics, vaccines, and gene therapy vectors — require batch-release endotoxin testing under FDA 21 CFR 610 and ICH Q6B. Our LAL COA satisfies IND, NDA, and ANDA submission requirements.
USP <797> mandates endotoxin testing for Category 2 compounded sterile preparations (CSPs) with beyond-use dates beyond 24 hours. Peptide and hormone injectables are a primary use case. We provide same-lot batch COAs formatted for pharmacy records.
Devices with blood-contacting or implantable surfaces must meet ISO 10993-11 and AAMI ST72 endotoxin limits. We test finished devices, components, and extractables per applicable standards and report results as EU/device or EU/cm².
Compounded injectable peptides (BPC-157, GHK-Cu, Sermorelin, AOD-9604, and others) require endotoxin testing prior to dispensing. Endotoxin limits for parenteral products are typically 5 EU/kg/hr maximum dose; a passing LAL COA is required before patient use.
In vivo rodent and primate studies are highly sensitive to endotoxin contamination — even sub-pyrogenic doses can confound cytokine, metabolic, and behavioral endpoints. Cell culture reagents destined for GMP or clinical applications also require endotoxin qualification.
API release testing, raw material qualification, and in-process controls for biologics manufacturing require endotoxin data as part of the batch record. We support CROs, CDMOs, and biotech sponsors with validated LAL testing integrated into your quality system.
Our endotoxin testing methods are aligned with the following pharmacopoeial and regulatory frameworks.
The primary U.S. pharmacopoeial standard for endotoxin testing. Defines LAL methods (gel-clot, turbidimetric, chromogenic), standard curve requirements, inhibition/enhancement controls, maximum valid dilution (MVD) calculations, and endotoxin limit specifications for pharmaceutical compendial articles.
The European pharmacopoeial equivalent of USP <85>, harmonized through the Pharmacopoeial Discussion Group (PDG). Required for products seeking CE marking or EMA approval. Our testing is conducted to satisfy both USP and Ph. Eur. requirements simultaneously.
FDA's 2012 guidance "Pyrogen and Endotoxins Testing: Questions and Answers" and related warning letters establish agency expectations for method validation, container-closure system effects, and matrix interference studies for injectable products.
Effective November 2023, USP <797> requires endotoxin testing for Category 2 CSPs. Requires the LAL test performed by a qualified laboratory with results documented in the batch record. Limits are calculated based on route of administration and maximum dose.
ICH guidance documents establish endotoxin specification setting for new chemical entities (Q6A) and biotechnological/biological products (Q6B) as part of the regulatory submission package. Endotoxin data must demonstrate batch-to-batch consistency and specification compliance.
Standards governing endotoxin testing for medical devices and biomaterials. AAMI ST72 provides specific guidance for extracting and testing endotoxin from device surfaces. ISO 10993-11 addresses systemic toxicity, including endotoxin as a pyrogenic risk in biocompatibility evaluation.
Endotoxin testing detects lipopolysaccharide (LPS) fragments from gram-negative bacteria that can cause fever, sepsis, or death if introduced into the bloodstream. The Limulus Amebocyte Lysate (LAL) method — standardized under USP <85> — is the gold standard for pharmaceutical and injectable products.
The LAL (Limulus Amebocyte Lysate) method uses a clotting enzyme from horseshoe crab blood that reacts specifically with bacterial endotoxins. Kinetic turbidimetric LAL measures the rate of clot formation to quantify endotoxin in Endotoxin Units (EU/mL or EU/mg) across a validated range.
USP <85> specifies endotoxin limits based on route of administration and dose. Injectable products must meet limits calculated as K/M, where K is 5 EU/kg/hr for non-intrathecal injections and M is the maximum dose per hour. Medical devices have limits based on the device type and surface area.
Standard endotoxin testing turnaround is 5–7 business days from sample receipt. Rush options may be available — contact us to discuss your timeline.
Yes. Compounded injectable peptides require endotoxin testing as part of USP <797> sterile compounding requirements. Endotoxin limits for parenteral administration are strict, and a LAL-method certificate of analysis is required before releasing batches for patient use.
Reach out via the form at /contact or call 1 (888) 589-4615. Provide your sample matrix, target endotoxin limit, and desired turnaround. We'll confirm methodology and shipping instructions within one business day.
Ship sealed, labeled samples in a secure secondary container to our San Diego laboratory. Minimum volume is typically 1 mL for liquid matrices. Include a completed chain-of-custody form (provided by us).
Results are delivered as a signed, ISO 17025-accredited COA via secure PDF within 5–7 business days of receipt. Expedited reporting is available on request.
Endotoxin testing is often ordered alongside the following services.
Contact us to discuss your matrix, endotoxin limit, and turnaround requirements. We'll confirm method applicability and provide a quote within one business day.